ACC

Main information

  • Trade name:
  • ACC Granules 200mg Milligram
  • Dosage:
  • 200mg Milligram
  • Pharmaceutical form:
  • Granules
  • Medicine domain:
  • Humans
  • Medicine type:
  • Allopathic drug

Documents

Localization

  • Available in:
  • ACC Granules 200mg Milligram
    Ireland
  • Language:
  • English

Other information

Status

  • Source:
  • HPRA - Health Products Regulatory Authority - Ireland
  • Authorization number:
  • PA0711/007/006
  • Authorization date:
  • 21-12-1998
  • Last update:
  • 14-10-2016

Summary of Product characteristics: dosage,interactions,side effects

PartII

SummaryofProductCharacteristics

1NAMEOFTHEMEDICINALPRODUCT

ACC200mgGranules

2QUALITATIVEANDQUANTITATIVECOMPOSITION

EachsachetofACC200mggranulescontainsAcetylcysteine200mg.

Forexcipients,see6.1.

3PHARMACEUTICALFORM

Granules

Whitegranuleswithanodourandtasteoforange.

4CLINICALPARTICULARS

4.1TherapeuticIndications

ACCisindicatedasanadjunctinthetreatmentofchronicbronchitisorotherrespiratoryconditionsassociatedwiththe

excessiveproductionofviscousmucous.

4.2Posologyandmethodofadministration

RouteofAdministration:

Oral.

RecommendedDosageSchedule:

AcuteTherapy-Adults(over14years):

OneSachet(200mg),3timesdaily.

Children2-6years:

OneSachet(200mg),2timesdaily.

Infantsunder2years:

Onesachet(200mg)daily.Thegranulesshouldbedissolvedinaglassofwater.

Inacuteexacerbationsatreatmentperiodof5-10daysisusuallyadequatebutmaybeextendedifnecessary.Inchronic

bronchitisreliefofsymptomsmaybenoticeableaftertreatmentfor1-2monthsbuttreatmentmaybeextendedforupto

sixmonths,e.g.duringwinterseason.Whenoralantibioticsordrugsarerequiredtheyshouldbeadministered2hours

apartfromAcetylcysteine.

4.3Contraindications

Irish Medicines Board

______________________________________________________________________________________________________________________

Date Printed 30/09/2006 CRN 2028454 page number: 1

ulceration.

4.4Specialwarningsandprecautionsforuse

Eachsachetcontainstheequivalentof2.8gofsucrose.Thisshouldbetakenintoaccountwhentreatingdiabetic

patients.ACCshouldbegiventonew-borninfantsonlyifabsolutelynecessary.

Patientswithrarehereditaryproblemsoffructoseintolerance,glucose-galactosemalabsorptionorsucrase-isomaltase

insufficiencyshouldnottakethismedicine.

4.5Interactionwithothermedicinalproductsandotherformsofinteraction

ACCshouldnotbeadministeredwithoralantibioticswiththeexceptionofamoxycillin,cefuroxim,doxycycline,

erythromycinandthiamphenicol.

TheconcomitantadministrationofACCwithoralantibioticsresultsinreductionoftheeffectivenessoftheantibiotics.

Antibioticsshouldbetakenatleast2hoursbeforeor2hoursaftertakingACC.

4.6Pregnancyandlactation

ACCgranulesandcapsulesshouldnotbeadministeredinpregnancyorduringlactation.

4.7Effectsonabilitytodriveandusemachines

Notapplicable.

4.8Undesirableeffects

Nausea,heartburn,vomiting,urticaria,headacheandtinnitushaveinfrequentlybeenreported,buttheserarely

necessitatethewithdrawaloftreatment.

Allergicskinreactions(itchingandurticaria)andbronchospasm,especiallyinasthmaticpatients,havebeenreported

rarelyinpatientstakingoralacetylcysteine.Highdosesofacetylcysteinegivenintravenouslyhavecaused

anaphylactoidreactions.

4.9Overdose

Thereisnospecificantidoteforacetylcysteineandtreatmentissymptomatic.Itconsistsofposturaldrainageand

bronchialsuctionandsupportivetherapyasindicated.

5PHARMACOLOGICALPROPERTIES

5.1Pharmacodynamicproperties

Acetylcysteinehasanintensemucolyticactiononmucoidandmucopurulentsecretionsduetoitsinabilitytosplit

disulphidebondsinmucousglycoprotein.Thispropertyallowsittobeusedasadjuvanttherapyinmanyclinical

conditionscharacterisedbythepresenceofviscousmucoidormucopurulentsecretionsparticularlyintherespiratory

tract.

5.2Pharmacokineticproperties

Irish Medicines Board

______________________________________________________________________________________________________________________

Date Printed 30/09/2006 CRN 2028454 page number: 2

5.3Preclinicalsafetydata

Notapplicable.

6PHARMACEUTICALPARTICULARS

6.1Listofexcipients

Sucrose

AscorbicAcid

SaccharinSodium

OrangeFlavourDry

1:1000Sotteri289

6.2Incompatibilities

Notapplicable.

6.3ShelfLife

Theshelf-lifeforACC200mggranulesis3years.

6.4Specialprecautionsforstorage

Donotstoreabove25 o

C.Storeintheoriginalpackagetoprotectfrommoisture.

6.5Natureandcontentsofcontainer

ACC200mggranulesarepackedinthermo-sealedsachetsmadeofatriplelayerfoilofaluminium-paperpolythene.

The80x49mmsachetsarepackedinoutercardboardcartons.

6.6Specialprecautionsfordisposalofausedmedicinalproductorwastematerialsderivedfrom

suchmedicinalproductandotherhandlingoftheproduct

Nospecialrequirements.

7MARKETINGAUTHORISATIONHOLDER

RowexLtd.

Bantry

Co.Cork

8MARKETINGAUTHORISATIONNUMBER

PA711/7/6

9DATEOFFIRSTAUTHORISATION/RENEWALOFTHEAUTHORISATION

Dateoffirstauthorisation:21December1998

Irish Medicines Board

______________________________________________________________________________________________________________________

Date Printed 30/09/2006 CRN 2028454 page number: 3

10DATEOFREVISIONOFTHETEXT

Irish Medicines Board

______________________________________________________________________________________________________________________

Date Printed 30/09/2006 CRN 2028454 page number: 4

20-12-2018

Terrific Care, LLC. / Medex Supply Dist, Inc. issues Nationwide Recall of CoaguChek Test Strips

Terrific Care, LLC. / Medex Supply Dist, Inc. issues Nationwide Recall of CoaguChek Test Strips

On 12/19/2018, Terrific Care, LLC. / Medex Supply Dist, Inc. initiated a nationwide recall of Roche CoaguChek test strips distributed directly to U.S. consumers by Terrific Care, LLC. / Medex Supply Dist, Inc. The products have been found to inaccurately report high INR test results.

FDA - U.S. Food and Drug Administration

1-11-2018

FDA warns patients and doctors about risk of inaccurate results from home-use device to monitor blood thinner warfarin

FDA warns patients and doctors about risk of inaccurate results from home-use device to monitor blood thinner warfarin

Roche Diagnostics issued voluntary recall of certain test strips used with CoaguChek meter devices; patients affected by the recall should seek alternative methods for testing.

FDA - U.S. Food and Drug Administration

11-9-2018

Novel foods: a risk profile for the house cricket (Acheta domesticus)

Novel foods: a risk profile for the house cricket (Acheta domesticus)

Published on: Tue, 28 Aug 2018 00:00:00 +0200 Novel foods could represent a sustainable alternative to traditional farming and conventional foodstuffs. Starting in 2018, Regulation (EU) 2283/2015 entered into force, laying down provisions for the approval of novel foods in Europe, including insects. This Approved Regulation establishes the requirements that enable Food Business Operators to bring new foods into the EU market, while ensuring high levels of food safety for European consumers. The present ...

Europe - EFSA - European Food Safety Authority Publications

7-9-2018

Orphan designation:  Recombinant human beta-glucuronidase (vestronidase alfa),  for the: Treatment of mucopolysaccharidosis type VII (Sly syndrome)

Orphan designation: Recombinant human beta-glucuronidase (vestronidase alfa), for the: Treatment of mucopolysaccharidosis type VII (Sly syndrome)

On 21 March 2012, orphan designation (EU/3/12/973) was granted by the European Commission to NDA Regulatory Science Ltd, United Kingdom, for recombinant human beta-glucuronidase for the treatment of mucopolysaccharidosis type VII (Sly syndrome).

Europe - EMA - European Medicines Agency

17-7-2018

Blokhuis kondigt grootschalige extra vaccinatie aan: Ruim half miljoen kinderen krijgen oproep

Blokhuis kondigt grootschalige extra vaccinatie aan: Ruim half miljoen kinderen krijgen oproep

Volgend jaar worden zo’n 650.000 kinderen extra opgeroepen om zich te laten inenten tegen de zeer ernstige infectieziekte meningokokken. Het gaat om kinderen die zijn geboren na 1 januari 2001 en voor mei 2004. Dat laat staatssecretaris Paul Blokhuis (VWS) weten in een brief aan de Tweede Kamer. Reden voor deze maatregel is dat in de afgelopen jaren een stijging te zien is van het aantal mensen dat de infectie meningokokken type W oploopt. Met deze extra vaccinatieronde moet die groei worden ingedamd. He...

Netherlands - Ministerie van Volksgezondheid, Welzijn en Sport

25-4-2018

Magnetic Resonance-guided Laser Interstitial Thermal Therapy (MRgLITT) Devices: Letter to Health Care Providers - Risk of Tissue Overheating Due to Inaccurate Magnetic Resonance Thermometry

Magnetic Resonance-guided Laser Interstitial Thermal Therapy (MRgLITT) Devices: Letter to Health Care Providers - Risk of Tissue Overheating Due to Inaccurate Magnetic Resonance Thermometry

FDA is currently evaluating data which suggests that potentially inaccurate MR thermometry information can be displayed during treatment. Posted 04/25/2018

FDA - U.S. Food and Drug Administration

20-3-2019

Today is #KickButtsDay. Take some time today to learn facts about the harms of smoking. 
#FACT Tobacco use causes more than 480,000 deaths each year in the United States. Find out more information to quit tobacco:  https://go.usa.gov/xEWdT  via @FDATobacc

Today is #KickButtsDay. Take some time today to learn facts about the harms of smoking. #FACT Tobacco use causes more than 480,000 deaths each year in the United States. Find out more information to quit tobacco: https://go.usa.gov/xEWdT  via @FDATobacc

Today is #KickButtsDay. Take some time today to learn facts about the harms of smoking. #FACT Tobacco use causes more than 480,000 deaths each year in the United States. Find out more information to quit tobacco: https://go.usa.gov/xEWdT  via @FDATobacco pic.twitter.com/vOvAFo6jO1

FDA - U.S. Food and Drug Administration

8-3-2019


Orphan designation: Acetylcysteine, Treatment of pseudomyxoma peritonei, 14/12/2018, Positive

Orphan designation: Acetylcysteine, Treatment of pseudomyxoma peritonei, 14/12/2018, Positive

Orphan designation: Acetylcysteine, Treatment of pseudomyxoma peritonei, 14/12/2018, Positive

Europe - EMA - European Medicines Agency

4-2-2019

On February 1st, @US_FDA classified a Class I Recall, the most serious   type of recall: Terrific Care, LLC. / Medex Supply Recalls CoaguChek XS  PT Test Strips Used to Monitor Blood Thinner Warfarin Due to Inaccurate  Test Results. Find out more here:  h

On February 1st, @US_FDA classified a Class I Recall, the most serious type of recall: Terrific Care, LLC. / Medex Supply Recalls CoaguChek XS PT Test Strips Used to Monitor Blood Thinner Warfarin Due to Inaccurate Test Results. Find out more here: h

On February 1st, @US_FDA classified a Class I Recall, the most serious type of recall: Terrific Care, LLC. / Medex Supply Recalls CoaguChek XS PT Test Strips Used to Monitor Blood Thinner Warfarin Due to Inaccurate Test Results. Find out more here: https://go.usa.gov/xEX7Y  pic.twitter.com/MeFubksqsa

FDA - U.S. Food and Drug Administration

4-2-2019

Feraccru (Norgine B.V.)

Feraccru (Norgine B.V.)

Feraccru (Active substance: ferric maltol) - Centralised - Transfer Marketing Authorisation Holder - Commission Decision (2019)857 of Mon, 04 Feb 2019 European Medicines Agency (EMA) procedure number: EMEA/H/C/2733/T/20

Europe -DG Health and Food Safety

29-1-2019

On Dec 28, 2018 @US_FDA  identified a Class I Recall, the most serious type of recall: Medtronic Recalls Synergy Cranial Software & Stealth Station S7 Cranial  Software Due to Inaccuracies Displayed During Surgical Procedures. Read  more about the recall:

On Dec 28, 2018 @US_FDA identified a Class I Recall, the most serious type of recall: Medtronic Recalls Synergy Cranial Software & Stealth Station S7 Cranial Software Due to Inaccuracies Displayed During Surgical Procedures. Read more about the recall:

On Dec 28, 2018 @US_FDA identified a Class I Recall, the most serious type of recall: Medtronic Recalls Synergy Cranial Software & Stealth Station S7 Cranial Software Due to Inaccuracies Displayed During Surgical Procedures. Read more about the recall: https://go.usa.gov/xEktg  pic.twitter.com/Hspup9pv4p

FDA - U.S. Food and Drug Administration

25-1-2019


Orphan designation: Sulfonated monophosphorylated mannose oligosaccharide, Treatment of hepatocellular carcinoma, 21/06/2011, Positive

Orphan designation: Sulfonated monophosphorylated mannose oligosaccharide, Treatment of hepatocellular carcinoma, 21/06/2011, Positive

Orphan designation: Sulfonated monophosphorylated mannose oligosaccharide, Treatment of hepatocellular carcinoma, 21/06/2011, Positive

Europe - EMA - European Medicines Agency

23-1-2019

EU/3/11/872 (S-cubed Pharmaceutical Services ApS)

EU/3/11/872 (S-cubed Pharmaceutical Services ApS)

EU/3/11/872 (Active substance: Sulfonated monophosphorylated mannose oligosaccharide) - Transfer of orphan designation - Commission Decision (2019)576 of Wed, 23 Jan 2019 European Medicines Agency (EMA) procedure number: EMA/OD/0000003129

Europe -DG Health and Food Safety

10-1-2019


Orphan designation: autologous CD34+ haematopoietic stem and progenitor cells genetically modified with the lentiviral vector IDUA LV, encoding for the alpha-L-iduronidase cDNA, Treatment of mucopolysaccharidosis type I, 26/10/2018, Positive

Orphan designation: autologous CD34+ haematopoietic stem and progenitor cells genetically modified with the lentiviral vector IDUA LV, encoding for the alpha-L-iduronidase cDNA, Treatment of mucopolysaccharidosis type I, 26/10/2018, Positive

Orphan designation: autologous CD34+ haematopoietic stem and progenitor cells genetically modified with the lentiviral vector IDUA LV, encoding for the alpha-L-iduronidase cDNA, Treatment of mucopolysaccharidosis type I, 26/10/2018, Positive

Europe - EMA - European Medicines Agency

18-12-2018

EU/3/18/2107 (MUCPharm Pty Ltd)

EU/3/18/2107 (MUCPharm Pty Ltd)

EU/3/18/2107 (Active substance: Acetylcysteine) - Orphan designation - Commission Decision (2018)9022 of Tue, 18 Dec 2018 European Medicines Agency (EMA) procedure number: EMA/OD/150/18

Europe -DG Health and Food Safety

2-11-2018

.@US_FDA  issues a class I recall: Roche Diagnostics recalls CoaguChek  XS PT Test  Strips due to inaccurate INR test results. Find out more:  https://go.usa.gov/xPVER  #FDA #MedicalDevicepic.twitter.com/EYmVZHrUZc

.@US_FDA issues a class I recall: Roche Diagnostics recalls CoaguChek XS PT Test Strips due to inaccurate INR test results. Find out more: https://go.usa.gov/xPVER  #FDA #MedicalDevicepic.twitter.com/EYmVZHrUZc

. @US_FDA issues a class I recall: Roche Diagnostics recalls CoaguChek XS PT Test Strips due to inaccurate INR test results. Find out more: https://go.usa.gov/xPVER  #FDA #MedicalDevice pic.twitter.com/EYmVZHrUZc

FDA - U.S. Food and Drug Administration

11-10-2018

October is #SIDSAwarenessMonth.  Smoking during pregnancy can lead to complications, premature delivery, low birth weight, stillbirth, and SIDS. Make sure your baby is #safetosleep at  https://women.smokefree.gov/  via @FDATobaccopic.twitter.com/i37QX61Bb

October is #SIDSAwarenessMonth. Smoking during pregnancy can lead to complications, premature delivery, low birth weight, stillbirth, and SIDS. Make sure your baby is #safetosleep at https://women.smokefree.gov/  via @FDATobaccopic.twitter.com/i37QX61Bb

October is #SIDSAwarenessMonth. Smoking during pregnancy can lead to complications, premature delivery, low birth weight, stillbirth, and SIDS. Make sure your baby is #safetosleep at https://women.smokefree.gov/  via @FDATobacco pic.twitter.com/i37QX61Bb7

FDA - U.S. Food and Drug Administration